These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
564 related articles for article (PubMed ID: 34669431)
41. Irritable bowel syndrome: a gut microbiota-related disorder? Bhattarai Y; Muniz Pedrogo DA; Kashyap PC Am J Physiol Gastrointest Liver Physiol; 2017 Jan; 312(1):G52-G62. PubMed ID: 27881403 [TBL] [Abstract][Full Text] [Related]
42. Gut microbiota and therapeutic approaches for dysbiosis in irritable bowel syndrome: recent developments and future perspectives. Dale HF; Lied GA Turk J Med Sci; 2020 Nov; 50(SI-2):1632-1641. PubMed ID: 32222124 [TBL] [Abstract][Full Text] [Related]
44. Progress with treating the microbial dysbiosis associated with irritable bowel syndrome. Pearson JS; Whorwell PJ Curr Opin Gastroenterol; 2017 Jan; 33(1):21-25. PubMed ID: 28134688 [TBL] [Abstract][Full Text] [Related]
45. Common mental disorders in irritable bowel syndrome: pathophysiology, management, and considerations for future randomised controlled trials. Staudacher HM; Mikocka-Walus A; Ford AC Lancet Gastroenterol Hepatol; 2021 May; 6(5):401-410. PubMed ID: 33587890 [TBL] [Abstract][Full Text] [Related]
46. The Brain-Gut-Microbiome System: Pathways and Implications for Autism Spectrum Disorder. Chernikova MA; Flores GD; Kilroy E; Labus JS; Mayer EA; Aziz-Zadeh L Nutrients; 2021 Dec; 13(12):. PubMed ID: 34960049 [TBL] [Abstract][Full Text] [Related]
47. The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders. Socała K; Doboszewska U; Szopa A; Serefko A; Włodarczyk M; Zielińska A; Poleszak E; Fichna J; Wlaź P Pharmacol Res; 2021 Oct; 172():105840. PubMed ID: 34450312 [TBL] [Abstract][Full Text] [Related]
48. Dietary Fibre Intervention for Gut Microbiota, Sleep, and Mental Health in Adults with Irritable Bowel Syndrome: A Scoping Review. Yan R; Andrew L; Marlow E; Kunaratnam K; Devine A; Dunican IC; Christophersen CT Nutrients; 2021 Jun; 13(7):. PubMed ID: 34201752 [TBL] [Abstract][Full Text] [Related]
49. Gut Microbiota and the Gut-Brain Axis: New Insights in the Pathophysiology of Metabolic Syndrome. de Clercq NC; Frissen MN; Groen AK; Nieuwdorp M Psychosom Med; 2017 Oct; 79(8):874-879. PubMed ID: 28557822 [TBL] [Abstract][Full Text] [Related]
51. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541 [TBL] [Abstract][Full Text] [Related]
52. Does Fibre-fix provided to people with irritable bowel syndrome who are consuming a low FODMAP diet improve their gut health, gut microbiome, sleep and mental health? A double-blinded, randomised controlled trial. Yan R; Murphy M; Genoni A; Marlow E; Dunican IC; Lo J; Andrew L; Devine A; Christophersen CT BMJ Open Gastroenterol; 2020 Aug; 7(1):. PubMed ID: 32816830 [TBL] [Abstract][Full Text] [Related]
54. Microbiome and Its Role in Irritable Bowel Syndrome. Pimentel M; Lembo A Dig Dis Sci; 2020 Mar; 65(3):829-839. PubMed ID: 32026278 [TBL] [Abstract][Full Text] [Related]
55. Aberrant Gut-To-Brain Signaling in Irritable Bowel Syndrome - The Role of Bile Acids. Ní Dhonnabháín R; Xiao Q; O'Malley D Front Endocrinol (Lausanne); 2021; 12():745190. PubMed ID: 34917022 [TBL] [Abstract][Full Text] [Related]
56. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Carabotti M; Scirocco A; Maselli MA; Severi C Ann Gastroenterol; 2015; 28(2):203-209. PubMed ID: 25830558 [TBL] [Abstract][Full Text] [Related]
57. The Intestinal Microbiota in the Irritable Bowel Syndrome. Collins SM Int Rev Neurobiol; 2016; 131():247-261. PubMed ID: 27793222 [TBL] [Abstract][Full Text] [Related]
58. A psychology of the human brain-gut-microbiome axis. Allen AP; Dinan TG; Clarke G; Cryan JF Soc Personal Psychol Compass; 2017 Apr; 11(4):e12309. PubMed ID: 28804508 [TBL] [Abstract][Full Text] [Related]
59. The gut microbiome and pharmacology: a prescription for therapeutic targeting of the gut-brain axis. Leprun PMB; Clarke G Curr Opin Pharmacol; 2019 Dec; 49():17-23. PubMed ID: 31082716 [TBL] [Abstract][Full Text] [Related]
60. Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders. Singh R; Zogg H; Ghoshal UC; Ro S Front Pharmacol; 2022; 13():808195. PubMed ID: 35145413 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]